The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

NCT03331393 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 265

Last updated 2022-07-06

No results posted yet for this study

Summary

The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).

Conditions

Interventions

OTHER

Non-interventional

Non-interventional

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-16
Primary Completion
2019-01-17
Completion
2019-01-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03331393 on ClinicalTrials.gov